Deal Ticker: Kellerhals Carrard advised Sofinnova Partners and Earlybird Venture Capital on financing round with HAYA Therapeutics
HAYA Therapeutics SA, a biotechnology company pioneering precision RNA-guided medicines, has announced that it has raised $65 million in Series A funding. The financing will accelerate the clinical development of HAYA’s lead long non-coding RNA (lncRNA) targeting candidate HTX-001 in heart failure and the continued expansion of its RNA-guided regulatory genome pipeline development engine. The RNA-guided regulatory genome targets therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases.
The round was led by Sofinnova Partners and Earlybird Venture Capital, with participation from Eli Lilly and Company (Lilly), ATHOS, +ND Capital, Alexandria Venture Investments and LifeLink Ventures, with additional support from existing investors Apollo Health Ventures, Longview Ventures (an affiliate of Broadview Ventures), 4see ventures, BERNINA Bioinvest and Schroders Capital.
We are pleased to have advised Sofinnova Partners and Earlybird Venture Capital on all Swiss legal aspects of this financing round by a team led by Nicolas Mosimann (VC/Life Sciences) and comprising Marco Sibold (tax), Kevin MacCabe (Corporate/VC), Sebastian Müller (Corporate/VC), Jan Bläuer (Corporate/VC) and Danijel Gajic (Corporate/VC).
Congratulations to the team at HAYA Therapeutics SA and the investors on this milestone!